 Mark Boguniewicz
Concepts (539)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 165 | 2025 | 329 | 24.530 |
Why?
| | Antibodies, Monoclonal, Humanized | 22 | 2024 | 806 | 3.170 |
Why?
| | Eczema | 14 | 2023 | 69 | 3.010 |
Why?
| | Severity of Illness Index | 50 | 2025 | 2837 | 2.040 |
Why?
| | Skin | 34 | 2024 | 749 | 1.880 |
Why?
| | Biological Products | 3 | 2024 | 220 | 1.700 |
Why?
| | Tacrolimus | 20 | 2023 | 200 | 1.690 |
Why?
| | Antibodies, Monoclonal | 9 | 2025 | 1430 | 1.580 |
Why?
| | Pruritus | 16 | 2024 | 63 | 1.480 |
Why?
| | Dermatologic Agents | 14 | 2024 | 70 | 1.440 |
Why?
| | Quality of Life | 30 | 2025 | 2889 | 1.380 |
Why?
| | Staphylococcus aureus | 15 | 2024 | 450 | 1.380 |
Why?
| | Practice Guidelines as Topic | 11 | 2025 | 1585 | 1.320 |
Why?
| | Asthma | 18 | 2025 | 2298 | 1.320 |
Why?
| | Staphylococcal Skin Infections | 8 | 2018 | 35 | 1.300 |
Why?
| | Immunosuppressive Agents | 15 | 2024 | 894 | 1.230 |
Why?
| | Keratinocytes | 12 | 2024 | 249 | 1.050 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2024 | 55 | 1.030 |
Why?
| | Double-Blind Method | 28 | 2025 | 1997 | 0.980 |
Why?
| | Calcineurin Inhibitors | 14 | 2010 | 73 | 0.910 |
Why?
| | Kaposi Varicelliform Eruption | 12 | 2013 | 21 | 0.890 |
Why?
| | Immunoglobulin E | 19 | 2024 | 345 | 0.890 |
Why?
| | Humans | 184 | 2025 | 137597 | 0.870 |
Why?
| | Boron Compounds | 3 | 2018 | 27 | 0.720 |
Why?
| | Cytokines | 17 | 2024 | 2085 | 0.710 |
Why?
| | Emollients | 4 | 2018 | 11 | 0.690 |
Why?
| | Urticaria | 3 | 2008 | 39 | 0.690 |
Why?
| | Hypersensitivity | 3 | 2023 | 257 | 0.690 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2020 | 8 | 0.680 |
Why?
| | Intermediate Filament Proteins | 7 | 2018 | 57 | 0.660 |
Why?
| | Treatment Outcome | 33 | 2025 | 10821 | 0.660 |
Why?
| | Janus Kinase Inhibitors | 3 | 2025 | 26 | 0.660 |
Why?
| | Administration, Topical | 16 | 2020 | 151 | 0.660 |
Why?
| | Adrenal Cortex Hormones | 11 | 2023 | 565 | 0.650 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2018 | 227 | 0.630 |
Why?
| | Bandages | 3 | 2016 | 37 | 0.610 |
Why?
| | Allergy and Immunology | 2 | 2017 | 43 | 0.610 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 256 | 0.600 |
Why?
| | Dermatology | 3 | 2017 | 127 | 0.600 |
Why?
| | Expert Testimony | 1 | 2019 | 39 | 0.590 |
Why?
| | Anti-Inflammatory Agents | 11 | 2020 | 496 | 0.580 |
Why?
| | Skin Care | 4 | 2008 | 25 | 0.580 |
Why?
| | Interleukin-13 | 11 | 2025 | 149 | 0.570 |
Why?
| | Interferon-gamma | 11 | 2013 | 789 | 0.570 |
Why?
| | Antimicrobial Cationic Peptides | 6 | 2010 | 81 | 0.570 |
Why?
| | Biological Therapy | 1 | 2017 | 29 | 0.550 |
Why?
| | Adult | 76 | 2025 | 37937 | 0.550 |
Why?
| | Food Hypersensitivity | 6 | 2024 | 183 | 0.540 |
Why?
| | Occlusive Dressings | 1 | 2016 | 5 | 0.520 |
Why?
| | Psoriasis | 12 | 2023 | 102 | 0.520 |
Why?
| | Interleukin-4 | 9 | 2023 | 216 | 0.490 |
Why?
| | Herpes Simplex | 3 | 2013 | 95 | 0.490 |
Why?
| | Advisory Committees | 1 | 2017 | 219 | 0.470 |
Why?
| | Child, Preschool | 33 | 2025 | 11106 | 0.460 |
Why?
| | Desensitization, Immunologic | 5 | 2024 | 96 | 0.460 |
Why?
| | Anti-Asthmatic Agents | 1 | 2019 | 397 | 0.450 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 127 | 0.450 |
Why?
| | Cost of Illness | 9 | 2018 | 308 | 0.450 |
Why?
| | Epidermis | 3 | 2017 | 157 | 0.450 |
Why?
| | beta-Defensins | 8 | 2010 | 21 | 0.430 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 3 | 2018 | 10 | 0.420 |
Why?
| | Simplexvirus | 3 | 2011 | 80 | 0.420 |
Why?
| | Glycyrrhetinic Acid | 3 | 2008 | 7 | 0.420 |
Why?
| | Conjunctivitis | 3 | 2023 | 30 | 0.420 |
Why?
| | Child | 44 | 2024 | 21985 | 0.420 |
Why?
| | Th2 Cells | 6 | 2017 | 176 | 0.410 |
Why?
| | Anti-Allergic Agents | 3 | 2014 | 46 | 0.410 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 410 | 0.400 |
Why?
| | Autoimmune Diseases | 4 | 2018 | 460 | 0.400 |
Why?
| | Hypersensitivity, Immediate | 3 | 2019 | 44 | 0.400 |
Why?
| | Calcineurin | 5 | 2006 | 108 | 0.390 |
Why?
| | Consensus | 5 | 2024 | 683 | 0.380 |
Why?
| | Adolescent | 38 | 2025 | 21558 | 0.370 |
Why?
| | Immunity, Innate | 6 | 2011 | 827 | 0.350 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 351 | 0.340 |
Why?
| | Allergens | 7 | 2023 | 409 | 0.340 |
Why?
| | Administration, Cutaneous | 9 | 2024 | 130 | 0.340 |
Why?
| | Male | 58 | 2025 | 67788 | 0.340 |
Why?
| | Drug Approval | 3 | 2020 | 88 | 0.330 |
Why?
| | Ointments | 10 | 2016 | 25 | 0.330 |
Why?
| | Adaptive Immunity | 1 | 2011 | 165 | 0.330 |
Why?
| | Plant Extracts | 3 | 2008 | 202 | 0.320 |
Why?
| | Infant | 24 | 2024 | 9482 | 0.320 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1052 | 0.320 |
Why?
| | Complementary Therapies | 1 | 2010 | 88 | 0.310 |
Why?
| | Dietary Fats | 2 | 2008 | 304 | 0.300 |
Why?
| | Comorbidity | 7 | 2025 | 1619 | 0.300 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 234 | 0.300 |
Why?
| | Off-Label Use | 2 | 2020 | 52 | 0.300 |
Why?
| | Disease Progression | 6 | 2019 | 2753 | 0.300 |
Why?
| | Female | 56 | 2025 | 73349 | 0.300 |
Why?
| | Staphylococcal Infections | 4 | 2023 | 400 | 0.300 |
Why?
| | Drug Hypersensitivity | 3 | 1995 | 90 | 0.300 |
Why?
| | Receptors, IgE | 1 | 2008 | 45 | 0.290 |
Why?
| | Population Groups | 2 | 2018 | 62 | 0.290 |
Why?
| | Prevalence | 12 | 2019 | 2731 | 0.280 |
Why?
| | Inflammation | 4 | 2018 | 2838 | 0.280 |
Why?
| | Chronic Disease | 12 | 2019 | 1794 | 0.280 |
Why?
| | Biomarkers | 8 | 2024 | 4155 | 0.270 |
Why?
| | Self Report | 7 | 2019 | 829 | 0.270 |
Why?
| | Disease Management | 5 | 2020 | 629 | 0.270 |
Why?
| | United States | 20 | 2024 | 14868 | 0.270 |
Why?
| | Rhinitis, Allergic | 2 | 2024 | 40 | 0.250 |
Why?
| | Chemokine CCL17 | 2 | 2024 | 6 | 0.250 |
Why?
| | Cross-Sectional Studies | 14 | 2021 | 5467 | 0.240 |
Why?
| | Anti-Bacterial Agents | 6 | 2023 | 1809 | 0.240 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2025 | 5 | 0.230 |
Why?
| | Dermatitis, Allergic Contact | 2 | 2016 | 73 | 0.230 |
Why?
| | Middle Aged | 38 | 2025 | 33450 | 0.230 |
Why?
| | Patch Tests | 3 | 2016 | 57 | 0.230 |
Why?
| | Vaccinia virus | 4 | 2011 | 43 | 0.230 |
Why?
| | Phototherapy | 3 | 2018 | 38 | 0.230 |
Why?
| | Sphingosine N-Acyltransferase | 1 | 2024 | 6 | 0.230 |
Why?
| | Omalizumab | 2 | 2020 | 51 | 0.230 |
Why?
| | Exanthema | 1 | 2005 | 78 | 0.220 |
Why?
| | Steroids | 3 | 2017 | 167 | 0.220 |
Why?
| | Aminopyridines | 1 | 2025 | 98 | 0.220 |
Why?
| | Diagnosis, Differential | 7 | 2008 | 1483 | 0.220 |
Why?
| | Benzamides | 1 | 2025 | 215 | 0.210 |
Why?
| | Ectropion | 1 | 2023 | 1 | 0.210 |
Why?
| | Janus Kinases | 1 | 2023 | 15 | 0.210 |
Why?
| | Blepharitis | 1 | 2023 | 5 | 0.200 |
Why?
| | Pain | 2 | 2019 | 756 | 0.200 |
Why?
| | Membrane Proteins | 5 | 2024 | 1164 | 0.200 |
Why?
| | Down-Regulation | 7 | 2017 | 656 | 0.200 |
Why?
| | Anxiety | 3 | 2019 | 1043 | 0.200 |
Why?
| | Sublingual Immunotherapy | 1 | 2022 | 5 | 0.200 |
Why?
| | Animals | 17 | 2024 | 36935 | 0.190 |
Why?
| | Receptors, Interleukin | 3 | 2020 | 45 | 0.190 |
Why?
| | Pyrimidines | 2 | 2024 | 471 | 0.190 |
Why?
| | Tight Junctions | 3 | 2011 | 76 | 0.190 |
Why?
| | Sickness Impact Profile | 2 | 2019 | 56 | 0.190 |
Why?
| | Cefuroxime | 1 | 2001 | 4 | 0.190 |
Why?
| | Recurrence | 4 | 2019 | 1061 | 0.180 |
Why?
| | Drug Industry | 2 | 2018 | 111 | 0.180 |
Why?
| | Cephalosporins | 1 | 2001 | 48 | 0.180 |
Why?
| | STAT6 Transcription Factor | 3 | 2011 | 27 | 0.180 |
Why?
| | Pyrazoles | 1 | 2024 | 424 | 0.180 |
Why?
| | Depression | 3 | 2019 | 1406 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2024 | 1477 | 0.170 |
Why?
| | Patient Education as Topic | 5 | 2015 | 766 | 0.170 |
Why?
| | Autoantibodies | 1 | 2008 | 1498 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 5 | 2024 | 401 | 0.170 |
Why?
| | Bacterial Toxins | 3 | 2012 | 106 | 0.170 |
Why?
| | Evidence-Based Medicine | 3 | 2024 | 740 | 0.170 |
Why?
| | Injections, Subcutaneous | 4 | 2023 | 157 | 0.160 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 165 | 0.160 |
Why?
| | Skin Diseases, Infectious | 3 | 2008 | 15 | 0.150 |
Why?
| | Vaccines | 1 | 2024 | 406 | 0.150 |
Why?
| | Patient Health Questionnaire | 1 | 2018 | 37 | 0.150 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 89 | 0.150 |
Why?
| | Drug Administration Schedule | 5 | 2025 | 786 | 0.150 |
Why?
| | Sulfonamides | 1 | 2022 | 513 | 0.150 |
Why?
| | Injections | 1 | 2019 | 182 | 0.140 |
Why?
| | Gene Expression Regulation | 7 | 2011 | 2607 | 0.140 |
Why?
| | Surveys and Questionnaires | 5 | 2019 | 5788 | 0.140 |
Why?
| | Immunologic Factors | 2 | 2005 | 236 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 6 | 2011 | 2427 | 0.140 |
Why?
| | Guidelines as Topic | 2 | 2018 | 275 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 290 | 0.130 |
Why?
| | Skin Diseases | 1 | 2019 | 149 | 0.130 |
Why?
| | T-Lymphocytes | 6 | 2006 | 1999 | 0.130 |
Why?
| | Skin Diseases, Viral | 2 | 2018 | 5 | 0.130 |
Why?
| | Young Adult | 12 | 2025 | 13223 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1309 | 0.130 |
Why?
| | Gloves, Surgical | 1 | 1996 | 4 | 0.130 |
Why?
| | Gloves, Protective | 1 | 1996 | 2 | 0.130 |
Why?
| | Latex | 1 | 1996 | 9 | 0.130 |
Why?
| | Rubber | 1 | 1996 | 7 | 0.130 |
Why?
| | Personal Satisfaction | 1 | 2018 | 207 | 0.130 |
Why?
| | Cells, Cultured | 13 | 2011 | 4193 | 0.120 |
Why?
| | Dermatitis, Occupational | 1 | 1996 | 14 | 0.120 |
Why?
| | Bronchial Hyperreactivity | 1 | 1996 | 111 | 0.120 |
Why?
| | Histamine H1 Antagonists | 2 | 2006 | 30 | 0.120 |
Why?
| | Chemokines, CC | 3 | 2006 | 33 | 0.120 |
Why?
| | Receptors, Cytokine | 2 | 2010 | 36 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 2 | 2019 | 807 | 0.120 |
Why?
| | Milk Proteins | 1 | 2015 | 34 | 0.120 |
Why?
| | Skin Cream | 2 | 2025 | 12 | 0.120 |
Why?
| | Milk Hypersensitivity | 1 | 2015 | 19 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 418 | 0.110 |
Why?
| | Primary Health Care | 2 | 2016 | 1750 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 324 | 0.110 |
Why?
| | Hydrotherapy | 1 | 2014 | 8 | 0.110 |
Why?
| | Infant Formula | 1 | 2015 | 75 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2019 | 546 | 0.110 |
Why?
| | Patient Care Planning | 1 | 2015 | 156 | 0.110 |
Why?
| | Patient-Centered Care | 2 | 2018 | 529 | 0.110 |
Why?
| | Skin Tests | 3 | 2012 | 101 | 0.110 |
Why?
| | Gene Expression Profiling | 4 | 2011 | 1768 | 0.110 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.110 |
Why?
| | Algorithms | 3 | 2018 | 1700 | 0.110 |
Why?
| | Recombinant Proteins | 6 | 2006 | 1356 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2020 | 2057 | 0.100 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2024 | 106 | 0.100 |
Why?
| | Risk Factors | 8 | 2015 | 10398 | 0.100 |
Why?
| | Health Status | 1 | 2018 | 792 | 0.100 |
Why?
| | Cholecalciferol | 1 | 2013 | 60 | 0.100 |
Why?
| | Lipids | 1 | 2017 | 671 | 0.100 |
Why?
| | Delphi Technique | 2 | 2024 | 281 | 0.100 |
Why?
| | Logistic Models | 4 | 2019 | 2070 | 0.100 |
Why?
| | RNA, Messenger | 10 | 2007 | 2834 | 0.100 |
Why?
| | Aged | 13 | 2019 | 23915 | 0.090 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 4 | 0.090 |
Why?
| | Vitamins | 1 | 2013 | 185 | 0.090 |
Why?
| | Eosinophils | 3 | 2024 | 334 | 0.090 |
Why?
| | Immunity, Cellular | 1 | 2013 | 268 | 0.090 |
Why?
| | Fibronectins | 2 | 2023 | 133 | 0.090 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 308 | 0.090 |
Why?
| | Vitamin D | 2 | 2013 | 397 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2011 | 2166 | 0.090 |
Why?
| | Research Design | 1 | 2018 | 1137 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2011 | 2189 | 0.090 |
Why?
| | Pharmaceutical Vehicles | 2 | 2008 | 12 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2010 | 1091 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 556 | 0.090 |
Why?
| | Signal Transduction | 2 | 2023 | 5084 | 0.090 |
Why?
| | Th1-Th2 Balance | 1 | 2010 | 8 | 0.080 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 162 | 0.080 |
Why?
| | Histamine Antagonists | 1 | 2010 | 21 | 0.080 |
Why?
| | Receptors, Chemokine | 1 | 2010 | 47 | 0.080 |
Why?
| | Glucocorticoids | 2 | 2013 | 596 | 0.080 |
Why?
| | Chickenpox Vaccine | 1 | 2010 | 73 | 0.080 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 28 | 0.080 |
Why?
| | Therapies, Investigational | 1 | 2010 | 17 | 0.080 |
Why?
| | Cathelicidins | 5 | 2010 | 41 | 0.080 |
Why?
| | Herpesviridae Infections | 1 | 2010 | 146 | 0.080 |
Why?
| | Genetic Variation | 2 | 2011 | 991 | 0.080 |
Why?
| | Adjuvants, Immunologic | 3 | 2004 | 226 | 0.080 |
Why?
| | Cardiovascular Diseases | 2 | 2018 | 2111 | 0.080 |
Why?
| | Hypertension | 1 | 2018 | 1298 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 3297 | 0.080 |
Why?
| | Coal Tar | 1 | 2008 | 3 | 0.080 |
Why?
| | Keratolytic Agents | 1 | 2008 | 5 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 1067 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 765 | 0.080 |
Why?
| | Mice | 9 | 2012 | 17789 | 0.070 |
Why?
| | Pediatrics | 2 | 2015 | 1102 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2013 | 561 | 0.070 |
Why?
| | Cell Degranulation | 1 | 2008 | 41 | 0.070 |
Why?
| | Disease Outbreaks | 1 | 2012 | 395 | 0.070 |
Why?
| | Pyroglyphidae | 2 | 2022 | 19 | 0.070 |
Why?
| | Irritants | 1 | 2008 | 43 | 0.070 |
Why?
| | Basophils | 1 | 2008 | 73 | 0.070 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.070 |
Why?
| | Dosage Forms | 1 | 2008 | 11 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 659 | 0.070 |
Why?
| | Aged, 80 and over | 6 | 2019 | 7590 | 0.070 |
Why?
| | United Kingdom | 2 | 2019 | 318 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2011 | 1243 | 0.070 |
Why?
| | Phenotype | 4 | 2023 | 3200 | 0.070 |
Why?
| | Combined Modality Therapy | 3 | 2014 | 1228 | 0.070 |
Why?
| | Environmental Exposure | 1 | 2012 | 579 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2064 | 0.070 |
Why?
| | Mast Cells | 1 | 2008 | 148 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1176 | 0.070 |
Why?
| | Reference Values | 2 | 2019 | 815 | 0.070 |
Why?
| | Herpesvirus 3, Human | 1 | 2010 | 332 | 0.070 |
Why?
| | Protein Precursors | 1 | 2007 | 134 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 904 | 0.070 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2006 | 11 | 0.070 |
Why?
| | Clinical Protocols | 1 | 2008 | 270 | 0.070 |
Why?
| | Drug Combinations | 3 | 2020 | 343 | 0.070 |
Why?
| | Patient Dropouts | 1 | 2007 | 67 | 0.060 |
Why?
| | Immunohistochemistry | 6 | 2010 | 1730 | 0.060 |
Why?
| | Cost-Benefit Analysis | 3 | 2018 | 592 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2020 | 347 | 0.060 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 63 | 0.060 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1143 | 0.060 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 2006 | 16 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2006 | 59 | 0.060 |
Why?
| | Virus Replication | 2 | 2006 | 483 | 0.060 |
Why?
| | Proteins | 2 | 2010 | 1009 | 0.060 |
Why?
| | Gene Frequency | 3 | 2013 | 521 | 0.060 |
Why?
| | Conjunctivitis, Allergic | 1 | 2025 | 4 | 0.060 |
Why?
| | Thiazoles | 1 | 2006 | 123 | 0.060 |
Why?
| | Immunoglobulins | 2 | 2005 | 171 | 0.060 |
Why?
| | Cyclopropanes | 1 | 2025 | 90 | 0.060 |
Why?
| | Thyroid Diseases | 1 | 2005 | 36 | 0.060 |
Why?
| | Models, Immunological | 1 | 2005 | 100 | 0.060 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2024 | 122 | 0.060 |
Why?
| | Academies and Institutes | 1 | 2004 | 53 | 0.050 |
Why?
| | Resorcinols | 1 | 2023 | 5 | 0.050 |
Why?
| | Interleukins | 1 | 2006 | 250 | 0.050 |
Why?
| | Immunoglobulin G | 2 | 2023 | 893 | 0.050 |
Why?
| | Stilbenes | 1 | 2023 | 35 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 225 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 172 | 0.050 |
Why?
| | Lactams | 2 | 1995 | 20 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2019 | 430 | 0.050 |
Why?
| | Gene Expression | 4 | 2007 | 1503 | 0.050 |
Why?
| | Janus Kinase 1 | 1 | 2023 | 24 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2005 | 302 | 0.050 |
Why?
| | STAT Transcription Factors | 1 | 2023 | 17 | 0.050 |
Why?
| | Acute Disease | 6 | 2008 | 1006 | 0.050 |
Why?
| | Interleukin-11 | 1 | 2003 | 10 | 0.050 |
Why?
| | Leukocyte Count | 2 | 1995 | 331 | 0.050 |
Why?
| | Patient Care Team | 1 | 2008 | 629 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 500 | 0.050 |
Why?
| | Risk | 2 | 2018 | 911 | 0.050 |
Why?
| | Prednisone | 2 | 1994 | 242 | 0.050 |
Why?
| | Dermatophagoides pteronyssinus | 1 | 2022 | 3 | 0.050 |
Why?
| | Patient Compliance | 1 | 2007 | 581 | 0.050 |
Why?
| | Conflict of Interest | 1 | 2004 | 130 | 0.050 |
Why?
| | Granuloma, Respiratory Tract | 1 | 2002 | 12 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 76 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2003 | 119 | 0.050 |
Why?
| | Insurance, Physician Services | 1 | 2002 | 4 | 0.050 |
Why?
| | Respiratory Sounds | 1 | 2023 | 125 | 0.050 |
Why?
| | Baths | 1 | 2022 | 14 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 3 | 2013 | 560 | 0.050 |
Why?
| | Prognosis | 3 | 2018 | 4009 | 0.050 |
Why?
| | Langerhans Cells | 1 | 2001 | 12 | 0.050 |
Why?
| | 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 12 | 0.050 |
Why?
| | Lymphoma | 2 | 2018 | 212 | 0.050 |
Why?
| | Caregivers | 2 | 2023 | 887 | 0.050 |
Why?
| | North America | 1 | 2022 | 313 | 0.050 |
Why?
| | Prospective Studies | 2 | 2020 | 7599 | 0.050 |
Why?
| | Superantigens | 1 | 2001 | 70 | 0.050 |
Why?
| | Ceramides | 1 | 2022 | 118 | 0.050 |
Why?
| | Immunotherapy | 1 | 2006 | 640 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2002 | 101 | 0.040 |
Why?
| | Time Factors | 2 | 2007 | 6829 | 0.040 |
Why?
| | Prodrugs | 1 | 2001 | 52 | 0.040 |
Why?
| | Claudin-1 | 2 | 2011 | 15 | 0.040 |
Why?
| | Beryllium | 1 | 2002 | 153 | 0.040 |
Why?
| | Bacterial Adhesion | 1 | 2001 | 100 | 0.040 |
Why?
| | Antigens, Bacterial | 1 | 2001 | 127 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4287 | 0.040 |
Why?
| | Placebos | 1 | 2021 | 199 | 0.040 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2000 | 8 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 407 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2859 | 0.040 |
Why?
| | Fibrinogen | 1 | 2001 | 170 | 0.040 |
Why?
| | Diet | 2 | 2022 | 1279 | 0.040 |
Why?
| | Health Expenditures | 1 | 2002 | 189 | 0.040 |
Why?
| | Injection Site Reaction | 1 | 2020 | 3 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 853 | 0.040 |
Why?
| | Markov Chains | 2 | 2015 | 126 | 0.040 |
Why?
| | Chemokines, CXC | 2 | 2003 | 70 | 0.040 |
Why?
| | Leg Dermatoses | 1 | 2019 | 1 | 0.040 |
Why?
| | Scalp Dermatoses | 1 | 2019 | 3 | 0.040 |
Why?
| | Foot Dermatoses | 1 | 2019 | 4 | 0.040 |
Why?
| | Buttocks | 1 | 2019 | 14 | 0.040 |
Why?
| | Hand Dermatoses | 1 | 2019 | 7 | 0.040 |
Why?
| | Facial Dermatoses | 1 | 2019 | 16 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3458 | 0.040 |
Why?
| | Fatty Acids | 1 | 2022 | 443 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2002 | 652 | 0.040 |
Why?
| | Genitalia | 1 | 2019 | 30 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 2011 | 23 | 0.040 |
Why?
| | Biopsy | 4 | 2007 | 1125 | 0.040 |
Why?
| | Genetic Association Studies | 2 | 2011 | 377 | 0.040 |
Why?
| | Torso | 1 | 2019 | 33 | 0.040 |
Why?
| | Interleukin-16 | 1 | 1998 | 6 | 0.040 |
Why?
| | Haplotypes | 2 | 2011 | 494 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 166 | 0.040 |
Why?
| | Skin Diseases, Bacterial | 1 | 2018 | 21 | 0.040 |
Why?
| | Autoantigens | 1 | 2001 | 430 | 0.040 |
Why?
| | Association | 1 | 2018 | 12 | 0.040 |
Why?
| | Dysbiosis | 1 | 2020 | 181 | 0.040 |
Why?
| | Thalidomide | 1 | 2018 | 40 | 0.040 |
Why?
| | Acetamides | 1 | 2018 | 36 | 0.040 |
Why?
| | Canada | 1 | 2020 | 410 | 0.040 |
Why?
| | Arm | 1 | 2019 | 104 | 0.040 |
Why?
| | Phthalic Acids | 1 | 2018 | 40 | 0.040 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2018 | 29 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 120 | 0.040 |
Why?
| | Herpesvirus 2, Human | 2 | 2009 | 29 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 391 | 0.030 |
Why?
| | Medicaid | 1 | 2002 | 435 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 374 | 0.030 |
Why?
| | Fundoplication | 1 | 1997 | 53 | 0.030 |
Why?
| | Immune System | 1 | 2018 | 178 | 0.030 |
Why?
| | Quinazolines | 1 | 2018 | 250 | 0.030 |
Why?
| | Pilot Projects | 2 | 1995 | 1712 | 0.030 |
Why?
| | Peak Expiratory Flow Rate | 2 | 1993 | 37 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2018 | 208 | 0.030 |
Why?
| | Monocytes | 2 | 2002 | 564 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2019 | 546 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 470 | 0.030 |
Why?
| | Texas | 2 | 2008 | 244 | 0.030 |
Why?
| | Proteomics | 1 | 2023 | 1110 | 0.030 |
Why?
| | Forced Expiratory Volume | 2 | 1997 | 531 | 0.030 |
Why?
| | Health Occupations | 1 | 1996 | 34 | 0.030 |
Why?
| | Interleukin-12 | 1 | 1996 | 121 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1996 | 297 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1381 | 0.030 |
Why?
| | Psychometrics | 1 | 2019 | 717 | 0.030 |
Why?
| | Whey Proteins | 1 | 2015 | 6 | 0.030 |
Why?
| | Penicillins | 1 | 1995 | 58 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 972 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 1997 | 234 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1509 | 0.030 |
Why?
| | Pyridines | 1 | 2018 | 504 | 0.030 |
Why?
| | Legionellosis | 1 | 1994 | 2 | 0.030 |
Why?
| | Legionnaires' Disease | 1 | 1994 | 4 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1996 | 138 | 0.030 |
Why?
| | Dermatitis, Irritant | 2 | 2004 | 10 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 961 | 0.030 |
Why?
| | Sleep | 1 | 2021 | 755 | 0.030 |
Why?
| | Nebulizers and Vaporizers | 1 | 1995 | 86 | 0.030 |
Why?
| | Anaphylaxis | 1 | 1996 | 105 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2010 | 1061 | 0.030 |
Why?
| | Milk | 1 | 2015 | 124 | 0.030 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 39 | 0.030 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 418 | 0.030 |
Why?
| | Long-Term Care | 1 | 2015 | 107 | 0.030 |
Why?
| | Methylprednisolone | 1 | 1994 | 86 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 152 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1285 | 0.030 |
Why?
| | Antigens | 1 | 1996 | 357 | 0.030 |
Why?
| | Cohort Studies | 2 | 2015 | 5725 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 553 | 0.030 |
Why?
| | Respiratory Physiological Phenomena | 1 | 1993 | 31 | 0.030 |
Why?
| | Immunologic Memory | 1 | 1996 | 354 | 0.030 |
Why?
| | Chemokine CXCL10 | 2 | 2009 | 39 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3567 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 191 | 0.030 |
Why?
| | Laparoscopy | 1 | 1997 | 466 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2006 | 1272 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2073 | 0.020 |
Why?
| | Genotype | 1 | 2018 | 1918 | 0.020 |
Why?
| | Chemokines | 2 | 2006 | 228 | 0.020 |
Why?
| | Cockroaches | 1 | 2012 | 22 | 0.020 |
Why?
| | Respiratory System | 1 | 1993 | 156 | 0.020 |
Why?
| | Treatment Failure | 1 | 1993 | 353 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2019 | 654 | 0.020 |
Why?
| | Haptens | 1 | 1992 | 22 | 0.020 |
Why?
| | Patient Care | 1 | 2013 | 111 | 0.020 |
Why?
| | Cats | 1 | 2012 | 210 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3271 | 0.020 |
Why?
| | Vaccinia | 1 | 2011 | 20 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2011 | 3018 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2015 | 578 | 0.020 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1991 | 29 | 0.020 |
Why?
| | Receptors, Interferon | 1 | 2011 | 52 | 0.020 |
Why?
| | Lung Diseases | 1 | 1997 | 767 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 412 | 0.020 |
Why?
| | Family | 1 | 2015 | 671 | 0.020 |
Why?
| | Microbiota | 1 | 2019 | 762 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 390 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2040 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2010 | 178 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2845 | 0.020 |
Why?
| | Chemokine CCL27 | 1 | 2009 | 1 | 0.020 |
Why?
| | Health Care Costs | 2 | 2003 | 398 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2799 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 398 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 3956 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 520 | 0.020 |
Why?
| | Interferon-beta | 1 | 2009 | 92 | 0.020 |
Why?
| | Lung | 1 | 2002 | 4060 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2194 | 0.020 |
Why?
| | Skin Physiological Phenomena | 1 | 2008 | 25 | 0.020 |
Why?
| | Herpesvirus 1, Human | 1 | 2009 | 87 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 121 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 13 | 0.020 |
Why?
| | Fluticasone | 1 | 2007 | 90 | 0.020 |
Why?
| | Chemokine CCL20 | 1 | 2006 | 5 | 0.020 |
Why?
| | Androstadienes | 1 | 2007 | 107 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 1998 | 313 | 0.020 |
Why?
| | Health Personnel | 1 | 2013 | 711 | 0.020 |
Why?
| | Thiazolidines | 1 | 2006 | 9 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2006 | 28 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 98 | 0.020 |
Why?
| | Vitis | 1 | 2006 | 42 | 0.020 |
Why?
| | Apoptosis | 1 | 1995 | 2554 | 0.010 |
Why?
| | Europe | 1 | 2006 | 414 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 2993 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2008 | 1313 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2009 | 628 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2005 | 63 | 0.010 |
Why?
| | Erythema | 1 | 2004 | 29 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2005 | 176 | 0.010 |
Why?
| | Genomics | 1 | 2010 | 795 | 0.010 |
Why?
| | Case Management | 1 | 2004 | 66 | 0.010 |
Why?
| | DNA, Viral | 1 | 2006 | 362 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2006 | 513 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6084 | 0.010 |
Why?
| | Collagen Type III | 1 | 2003 | 16 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5646 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2006 | 318 | 0.010 |
Why?
| | Retreatment | 1 | 2003 | 72 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2006 | 484 | 0.010 |
Why?
| | Collagen Type I | 1 | 2003 | 136 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 22 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2181 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2003 | 165 | 0.010 |
Why?
| | Immunoblotting | 1 | 2002 | 308 | 0.010 |
Why?
| | Societies, Medical | 1 | 2006 | 819 | 0.010 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2003 | 99 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 817 | 0.010 |
Why?
| | Health Services | 1 | 2003 | 106 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1200 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2003 | 324 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 189 | 0.010 |
Why?
| | Cooperative Behavior | 1 | 2004 | 452 | 0.010 |
Why?
| | Chemotactic Factors, Eosinophil | 1 | 2000 | 7 | 0.010 |
Why?
| | Up-Regulation | 1 | 2003 | 840 | 0.010 |
Why?
| | Chemokine CCL11 | 1 | 2000 | 26 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2001 | 180 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1993 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 336 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2004 | 666 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 483 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 2001 | 153 | 0.010 |
Why?
| | Odds Ratio | 1 | 2003 | 1068 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 245 | 0.010 |
Why?
| | Receptors, Interleukin-12 | 1 | 1998 | 7 | 0.010 |
Why?
| | Receptors, Interleukin-5 | 1 | 1998 | 6 | 0.010 |
Why?
| | Receptors, Interleukin-4 | 1 | 1998 | 16 | 0.010 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 15 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2139 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 1193 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 967 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2900 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2006 | 15619 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1782 | 0.010 |
Why?
| | Colorado | 1 | 2006 | 4576 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 1997 | 601 | 0.010 |
Why?
| | Immunocompetence | 1 | 1994 | 42 | 0.010 |
Why?
| | Interleukin-5 | 1 | 1994 | 44 | 0.010 |
Why?
| | Methacholine Chloride | 1 | 1993 | 52 | 0.010 |
Why?
| | Bronchial Provocation Tests | 1 | 1993 | 51 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1994 | 303 | 0.010 |
Why?
| | Aerosols | 1 | 1993 | 176 | 0.010 |
Why?
| | Interleukin-8 | 1 | 1993 | 268 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1993 | 201 | 0.010 |
Why?
| | Bronchi | 1 | 1993 | 260 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1993 | 688 | 0.010 |
Why?
| | Cell Survival | 1 | 1995 | 1120 | 0.010 |
Why?
| | Enterotoxins | 1 | 1991 | 88 | 0.010 |
Why?
| | Macrophages, Alveolar | 1 | 1993 | 391 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1991 | 146 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1991 | 132 | 0.010 |
Why?
| | Neoplasms | 1 | 2005 | 2657 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1993 | 965 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1993 | 1457 | 0.000 |
Why?
|
|
Boguniewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|